Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)

Trial Profile

Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TACo-BEAT-MBM
  • Most Recent Events

    • 16 Oct 2019 Drug cobimetinib is added in Experimental Arm. Endpoint of Safety, tolerability, and efficacy is added. Planned patient number increased from 40-60.
    • 10 Oct 2019 Planned number of patients changed from 40 to 60.
    • 10 Oct 2019 Planned primary completion date changed from 1 Jun 2020 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top